Pay in 4 interest-free payments of $6.25 Learn more
Ships within 48 hours · Estimated delivery Aug 24 - Aug 29
The risk profile is not only clinical but also regulatory , requiring vigilance at the dispensing stage
Some research shows it could benefit heart function, though evidence is mixed
A randomized, placebo-controlled, phase II trial of intravenous allogeneic non-HLA matched, unrelated donor cord blood infusion for ischemic stroke
This is often accompanied by an improved clinical presentation and more favorable laboratory parameters
US$ 20.94
US$ 26.77
US$ 29.39
US$ 21.73
US$ 23.04
US$ 20.50
US$ 23.30
US$ 20.06
